Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Current Liabilities

v3.23.1
Accrued Expenses and Other Current Liabilities
 6 Months Ended
Mar. 31, 2023
Payables and Accruals [Abstract]  
Accrued Expenses and Other Current Liabilities

3. Accrued Expenses and Other Current Liabilities

 

Accrued expenses and other current liabilities consisted of the following:

 

    March 31,     September 30,  
    2023     2022  
Compensation and benefits   $ 1,801,489     $ 1,218,530  
Research and development     692,477       1,593,922  
Professional fees     325,927       378,890  
Other     292,389       2,630  
 Accrued expenses and other current liabilities   $ 3,112,282     $ 3,193,972  

 

 

Sonnet BioTherapeutics Holdings, Inc.

Notes to Unaudited Interim Consolidated Financial Statements